For example, despite over 90% of pre-B cells in ALL expressing CD22, the presence of CD22-negative sub-populations of ALL cells or cells with reduced can lead to resistance against CD22-targeted immunotherapy [127, 128]. Here, CD22 is linked to acute lymphoblastic leukemia.